Tempest Therapeutics Completes Asset Acquisition, Issues Warrants, and Announces Leadership Changes

summarizeSummary

Tempest Therapeutics completed a highly dilutive asset acquisition, resulting in a change of control, issued millions of warrants, and announced significant executive and board leadership changes.

check_boxKey Events

• Completes Asset Acquisition

  Tempest Therapeutics completed the acquisition of CAR T-cell therapy assets from Erigen LLC and Factor Bioscience Inc., as previously approved by stockholders on 2026-01-28.

• Significant Share Issuance and Change of Control

  The company issued 8,268,495 shares of common stock for the acquisition, resulting in Erigen LLC owning approximately 61.3% of the outstanding shares and a change in control. This issuance represents a value of $19.8 million, significantly diluting existing shareholders.

• Warrant Distribution to Shareholders

  Tempest Therapeutics issued 6,784,989 warrants as a dividend, with each warrant entitling the holder to purchase one share of common stock at an exercise price of $18.48. These warrants expire on February 3, 2031, and represent substantial potential future dilution.

• Executive and Board Leadership Changes

  Geoff Nichol resigned from the Board, and Michael Raab transitioned from Board Chair to Stephen Brady. Stephen Brady also resigned as President and CEO, with Matthew Angel (co-founder of the acquired entity) appointed as the new President and CEO and a Class I director.

auto_awesomeAnalysis

Tempest Therapeutics has completed a highly dilutive asset acquisition, issuing 8.27 million shares of common stock to Erigen LLC and Factor Bioscience Inc. for CAR T-cell therapy assets. This transaction results in Erigen LLC gaining majority ownership (approximately 61.3%) of Tempest Therapeutics, fundamentally altering the company's control and strategic direction. The value of shares issued for the acquisition ($19.8 million) significantly exceeds the company's prior market capitalization, indicating a substantial dilution for existing shareholders. Concurrently, the company distributed 6.78 million warrants to existing shareholders, exercisable at $18.48 per share, which represents a potential additional dilution of over 50% if exercised. These warrants are deeply out-of-the-money compared to the current stock price, but create a significant overhang. The filing also details a complete overhaul of the executive leadership and board, with the CEO and a director resigning, and Matthew Angel (co-founder of the acquired entity) appointed as the new President and CEO. These changes are a direct consequence of the change in control and the asset acquisition, marking a pivotal moment for the company.